Traditionally, Golden Tickets lead to chocolate rivers or everlasting gobstoppers. For biotech startups, though, Golden Tickets lead to something with (potentially) fewer pitfalls: money from major pharmaceutical companies.
On Thursday, Pfizer (PFE) announced it would give two startups, Neutrolis and Mediar Therapeutics, so-called Golden Tickets to LabCentral, a noted Cambridge, Mass., biotech incubator. The tickets act as vouchers for the cost of a bench in the incubator for a year. In theory, it sounds like a grand opportunity. But in reality, what has it meant for past recipients?